AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate
AstraZeneca PLC (LON: AZN) has revised its COVID-19 vaccine efficacy rating after concluding a more extensive study previously done.
Full Article
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate
Motley Fool
0 shares
3 views
You might like
Related news coverage
The United Nations In The Fight Against Covid – Analysis
Eurasia Review
The nature of the global Covid pandemic cries out for a multilateral intergovernmental resolution. Yet so far nothing has been..
-
Dow's late fall into the red not enough to slow best month since November
Proactive Investors
-
Wall Street in the green at midday following jump in jobs data; Dow teeters on the flatline
Proactive Investors
-
COVID: BioNTech-Pfizer vaccine shows '100% efficacy' for young teens
Deutsche Welle
-
Shots in little arms: COVID-19 vaccine testing turns to kids
SeattlePI.com
Advertisement
More coverage
After US rebuke, AstraZeneca releases new vaccine data
IndiaTimes
AstraZeneca reiterated on Wednesday that its Covid-19 vaccine was very effective at preventing the disease, based on more recent..
-
Doctor on new AstraZeneca vaccine data, media coverage of pandemic
CBS News
-
Businessinsider.co.za | AstraZeneca revises down its vaccine efficacy in a huge US trial - from 79% to 76%
News24
-
Vial flaws deal fresh blow to Hong Kong vaccinations
MENAFN.com
-
AstraZeneca revises down its vaccine efficacy in a huge US trial, from 79% to 76%, following concerns from Fauci and other experts that the results were outdated
Business Insider